$4.45
-0.01(-0.34%)
Mkt Cap $94M
$1.35
$7.13
52-Week Range
At a Glance
AI-generatedCAMP4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, reported a net loss of $80.4 million for FY 2025, up 55% from $51.8 million in FY 2024, driven by a $29.8 million non-cash expense from the change in fair value of derivative tranche liability.
Revenue breakdown: RD (100%).
8-K
CAMP4 Therapeutics Corporation appointed Michael MacLean as a Class III director effective April 1, 2026, increasing the Board size from eight to nine members. He was also appointed to the Audit Committee and Compensation Committee, and will receive an option to purchase 56,000 shares of common stock vesting monthly over three years under the amended Non-Employee Director Compensation Policy.$94M
Market Cap
$1M
Revenue
-$33M
Net Income
Employees55
Fundamentals
How The Business Makes Money
Revenue by Segment
RD100%($4M)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001736730
ISINUS13463J1016
CUSIP13463J101
Phone617-651-8867
AddressOne Kendall Square Bldg 1400 West, 3rd Floor, Cambridge, MA, 02139, US
SEC EDGAR